AFMD Affimed N.V.

Affimed Announces Fourth Quarter and Year End 2017 Financial Results and Corporate Update Conference Call

Affimed Announces Fourth Quarter and Year End 2017 Financial Results and Corporate Update Conference Call

Heidelberg, Germany, March 13, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on March 20, 2018, the Company will release its financial results for the quarter and year ended December 31, 2017. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, March 20, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3160515.

United States:

Germany: +49 (0)69 2222 13420

Netherlands: +31 (0) 20 721 9251

Denmark:

France: +33 (0)1 76 77 22 74

Switzerland: +41 (0)22 567 5729

United Kingdom:+44 (0)330 336 9105

An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at . A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit .

Contact:

Anca Alexandru, Head of Communications, EU IR

Phone: 41

E-Mail: ,

EN
13/03/2018

Underlying

AFMDAffimed N.V.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Affimed N.V.

 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Reports 2023 Financial Results and Operational Progress

Affimed Reports 2023 Financial Results and Operational Progress AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily pretreated patients who were evaluated. Mature progression free survival (PFS) data from the 15 EGFR-wildtype NSCLC patients and initial efficacy data from the EGFR-mutant NSCLC cohorts are expected in Q2 2024.Acimtamig (AFM13) combination with...

March 28, 2024 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed To Report Full Year 2023 Financial Results & Corporate Update ...

Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024 MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be a...

March 21, 2024 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces 1-for-10 Reverse Stock Split

Affimed Announces 1-for-10 Reverse Stock Split MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the Company, with prior approval of the Company’s supervisory board and management board, intends to effect a 1-for-10 reverse stock split of its outstanding common shares, par value €0.01 (“Common Shares”) per share. The reverse stock split is expected to be effected after market close on March 8, 202...

March 6, 2024 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-w...

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohortFollow-up shows three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still awaiting a confirmatory scanStudy to be expanded to a total of 40 EGFRwt NSCLC patientsEnrollment in the EGFR-mutant (mut) NSCLC cohort is ongoingData from both the EGFRwt and EGFRmut cohorts expected in H1 ...

January 8, 2024 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Leadership Change and Organizational Restructuring

Affimed Announces Leadership Change and Organizational Restructuring Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025Go forward organization will focus on advancing clinical programsCompany confirms guidance on data readouts for AFM24-102 and LuminICE-203 in H1 2024 MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) --  Affimed N.V. (Nasdaq: AFMD) (the "Company" or "Affimed"), a clinical-stage immuno-oncology company committed to giving patient...

January 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch